[{"orgOrder":0,"company":"Allderma","sponsor":"Moberg Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Terbinafine","moa":"Squalene monooxygenase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Allderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Allderma \/ Allderma","highestDevelopmentStatusID":"15","companyTruncated":"Allderma \/ Allderma"}]

Find Clinical Drug Pipeline Developments & Deals by Allderma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          BioProcess International
                          Not Confirmed
                          BioProcess International
                          Not Confirmed

                          Details : The agreement with Allderma complements the existing licensing agreement for MOB-015 in Europe. Allderma is responsible for marketing, distribution and sales in Sweden, Denmark and Norway, while Moberg Pharma is responsible for the manufacture and delive...

                          Product Name : Terclara

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          August 11, 2021

                          Lead Product(s) : Terbinafine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Recipient : Moberg Pharma

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank